As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.
The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.